Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Although in vitro observations suggest that cross-presentation of antigens is mediated primarily by CD8alpha+ dendritic cells, in vivo analysis has been hampered by the lack of systems that selectively eliminate this cell lineage. We show that deletion of the transcription factor Batf3 ablated development of CD8alpha+ dendritic cells, allowing us to examine their role in immunity in vivo. Dendritic cells from Batf3-/- mice were defective in cross-presentation, and Batf3-/- mice lacked virus-specific CD8+ T cell responses to West Nile virus. Importantly, rejection of highly immunogenic syngeneic tumors was impaired in Batf3-/- mice. These results suggest an important role for CD8alpha+ dendritic cells and cross-presentation in responses to viruses and in tumor rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“appears essential for T cell-driven antitumor immunity (Hildner et al., 2008)”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
In the citing paper
“Both DC1s and DC2s expressed the DC markers Batf3, Flt3, H2-Dmb2 and Zbtb46 (Meredith et al., 2012; Hildner et al., 2008;); DC1 expressed Fscn1 and Ly 75 (DEC-205) whereas DC2s expressed CD209a (DC- SIGN), Mgl2 (CD301b) and Cd24a (Figure 2B and Figure S2B).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citationJung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Barnden, M. J., Allison, J., Heath, W. R., & Carbone, F. R. (1998) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1998.00709.x · Cited by 1,489
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,328
Steady-state and inflammatory dendritic-cell development
Shortman, K., & Naik, S. H. (2007) · Nature Reviews Immunology · doi:10.1038/nri1996 · Cited by 1,190
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Bevan, M. J. (1976) · The Journal of experimental medicine · doi:10.1084/jem.143.5.1283 · Cited by 956
Toll-like receptor 3 promotes cross-priming to virus-infected cells
Schulz, O., Diebold, S. S., Chen, M., Näslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y.-T., Flavell, R. A., Liljeström, P., & Reis e Sousa, C. (2005) · Nature · doi:10.1038/nature03326 · Cited by 921
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Cited by
Items 201–300 of 1,008
Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells
Du, X., Wen, J., Wang, Y., Karmaus, P. W. F., Khatamian, A., Tan, H., Li, Y., Guy, C., Nguyen, T.-L. M., Dhungana, Y., et al. (2018) · Nature · doi:10.1038/s41586-018-0177-0 · Cited by 223
Lecoultre, M., Dutoit, V., & Walker, P. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001408 · Cited by 223
Mayer, C. T., Ghorbani, P., Nandan, A., Dudek, M., Arnold-Schrauf, C., Hesse, C., Berod, L., Stüve, P., Puttur, F., Merad, M., et al. (2014) · Blood · doi:10.1182/blood-2013-12-545772 · Cited by 219
McCartney, S., Vermi, W., Gilfillan, S., Cella, M., Murphy, T. L., Schreiber, R. D., Murphy, K. M., & Colonna, M. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20091181 · Cited by 216
“This possibility was further supported by a recent study showing that poly(I:C) triggers the TRIF and IPS1 signaling pathways in CD8 DCs, inducing the secretion of IL-12 and type I IFNs that activate NK cells in vitro (Miyake et al., 2009).”
InfluentialAdjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?
Ho, N. I., Huis in 't Veld, L. G. M., Raaijmakers, T. K., & Adema, G. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02874 · Cited by 216
“, Batf3 mice or zinc finger transcription factor knockout studies, have provided important insight in the functional role of DC subsets in antigen presentation (50, 51).”
BackgroundBaker, K., Qiao, S.-W., Kuo, T. T., Aveson, V. G., Platzer, B., Andersen, J.-T., Sandlie, I., Chen, Z., de Haar, C., Lencer, W. I., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019037108 · Cited by 216
Iborra, S., Martínez-López, M., Khouili, S. C., Enamorado, M., Cueto, F. J., Conde-Garrosa, R., del Fresno, C., & Sancho, D. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.019 · Cited by 216
“…analyzed CD8+ T cell immunity to VACV intradermal (i.d.) infection comparing WTmice with two independent genetic mouse models with deficient crosspresentation of VACV antigens: DNGR-1-deficient mice (Clec9agfp/gfp) (Iborra et al., 2012) and Batf3 / mice (Hildner et al., 2008; Seillet et al., 2013).”
InfluentialMeyer, M. A., Baer, J. M., Knolhoff, B. L., Nywening, T. M., Panni, R. Z., Su, X., Weilbaecher, K. N., Hawkins, W. G., Ma, C., Fields, R. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03600-6 · Cited by 217
Innate Immunity and Cancer Pathophysiology
Maiorino, L., Daßler-Plenker, J., Sun, L., & Egeblad, M. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032221-115501 · Cited by 215
Designing Cancer Immunotherapies That Engage T Cells and NK Cells
Kyrysyuk, O., & Wucherpfennig, K. W. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-044122 · Cited by 213
Features of the dendritic cell lineage
Steinman, R. M., & Idoyaga, J. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00888.x · Cited by 215
Nagao, K., Ginhoux, F., Leitner, W. W., Motegi, S.-I., Bennett, C. L., Clausen, B. E., Merad, M., & Udey, M. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807126106 · Cited by 215
Wiesner, D. L., Specht, C. A., Lee, C. K., Smith, K. D., Mukaremera, L., Lee, S. T., Lee, C. G., Elias, J. A., Nielsen, J. N., Boulware, D. R., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004701 · Cited by 214
Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease
Zhao, G.-N., Jiang, D.-S., & Li, H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.030 · Cited by 212
Origin and functional heterogeneity of non‐lymphoid tissue dendritic cells in mice
Helft, J., Ginhoux, F., Bogunovic, M., & Merad, M. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00885.x · Cited by 210
Roberti, M. P., Yonekura, S., Duong, C. P. M., Picard, M., Ferrere, G., Tidjani Alou, M., Rauber, C., Iebba, V., Lehmann, C. H. K., Amon, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0882-8 · Cited by 208
Kamphorst, A. O., Guermonprez, P., Dudziak, D., & Nussenzweig, M. C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001205 · Cited by 208
“Similarly, CD8 DCs are the preferred Ag cross-presenting cells in viral (29, 58) or L.”
BackgroundBriseño, C. G., Haldar, M., Kretzer, N. M., Wu, X., Theisen, D. J., KC, W., Durai, V., Grajales-Reyes, G. E., Iwata, A., Bagadia, P., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.025 · Cited by 208
“In contrast, Batf3 is required for the development of cDCs capable of cross-presentation (Hildner et al., 2008; Torti et al., 2011), and Irf4 was shown to be required for MHC-II expression in GM-DCs (Vander Lugt et al.”
BackgroundAnandasabapathy, N., Victora, G. D., Meredith, M., Feder, R., Dong, B., Kluger, C., Yao, K., Dustin, M. L., Nussenzweig, M. C., Steinman, R. M., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102657 · Cited by 207
“For transcription factors that program DC differentiation, m/chDCs demonstrated high expression of mRNAs for transcription factors Batf3, Id2, and RBP-J, each known to be involved in the differentiation of CD8+ DCs in spleen (Fig. 4 E; Hacker et al., 2003; Caton et al., 2007; Hildner et al., 2008), suggesting a simila…”
BackgroundNotch Signaling Facilitates In Vitro Generation of Cross-Presenting Classical Dendritic Cells
Kirkling, M. E., Cytlak, U., Lau, C. M., Lewis, K. L., Resteu, A., Khodadadi-Jamayran, A., Siebel, C. W., Salmon, H., Merad, M., Tsirigos, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.068 · Cited by 205
“Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow.”
BackgroundInfluentialMeiser, P., Knolle, M. A., Hirschberger, A., de Almeida, G. P., Bayerl, F., Lacher, S., Pedde, A.-M., Flommersfeld, S., Hönninger, J., Stark, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.008 · Cited by 203
Predicting measures of soil health using the microbiome and supervised machine learning
Wilhelm, R. C., van Es, H. M., & Buckley, D. H. (2022) · Soil Biology and Biochemistry · doi:10.1016/j.soilbio.2021.108472 · Cited by 203
Bayerl, F., Meiser, P., Donakonda, S., Hirschberger, A., Lacher, S. B., Pedde, A.-M., Hermann, C. D., Elewaut, A., Knolle, M., Ramsauer, L., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.05.011 · Cited by 203
Human dendritic cell subsets and function in health and disease
O’Keeffe, M., Mok, W. H., & Radford, K. J. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2005-0 · Cited by 203
Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies
Panni, R. Z., Herndon, J. M., Zuo, C., Hegde, S., Hogg, G. D., Knolhoff, B. L., Breden, M. A., Li, X., Krisnawan, V. E., Khan, S. Q., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau9240 · Cited by 201
Adaptive (T and B Cells) Immunity and Control by Dendritic Cells in Atherosclerosis
Ait-Oufella, H., Sage, A. P., Mallat, Z., & Tedgui, A. (2014) · Circulation Research · doi:10.1161/circresaha.114.302761 · Cited by 201
“Transcription factors influencing these lineages include zinc finger and BTB domain containing 46 (Zbtb46) and basic leucine zipper transcription factor ATF-like 3 (BATF3) for pre-cDCs(221) and transcription factor 4 (Tcf4) for pDCs.(225,226) Pre-cDCs directly entering lymphoid tissue become specialized lymphoid resid…”
BackgroundCancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
Conniot, J., Silva, J. M., Fernandes, J. G., Silva, L. C., Gaspar, R., Brocchini, S., Florindo, H. F., & Barata, T. S. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00105 · Cited by 200
“These molecules or cells can target specific receptors, leading to enhanced efficacy of the treatment and also to fewer side effects.”
BackgroundCohn, L., Chatterjee, B., Esselborn, F., Smed-Sörensen, A., Nakamura, N., Chalouni, C., Lee, B.-C., Vandlen, R., Keler, T., Lauer, P., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121251 · Cited by 200
“In the mouse, there is excellent evidence to suggest that the CD8+ DC subset, especially in the spleen, plays a key role in antigen cross presentation in vivo (Dudziak et al., 2007; Hildner et al., 2008).”
BackgroundSchraml, B. U., & Reis e Sousa, C. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.11.001 · Cited by 197
Self-citationBachem, A., Hartung, E., Güttler, S., Mora, A., Zhou, X., Hegemann, A., Plantinga, M., Mazzini, E., Stoitzner, P., Gurka, S., et al. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00214 · Cited by 195
“…specific gene expression pattern with splenic “classical CD8+ DCs” (Edwards et al., 2003; Edelson et al., 2010; Crozat et al., 2011), and are dependent on the TFs Batf3, IRF-8, and Id2 (Schiavoni et al., 2002; Aliberti et al., 2003; Hildner et al., 2008; Ginhoux et al., 2009; Edelson et al., 2010).”
BackgroundInfluentialAntigen processing and presentation
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.07.005 · Cited by 194
A Clonogenic Progenitor with Prominent Plasmacytoid Dendritic Cell Developmental Potential
Onai, N., Kurabayashi, K., Hosoi-Amaike, M., Toyama-Sorimachi, N., Matsushima, K., Inaba, K., & Ohteki, T. (2013) · Immunity · doi:10.1016/j.immuni.2013.04.006 · Cited by 193
“, 2003), Batf3 is required for CD8a and CD103 cDC development (Hildner et al., 2008; Edelson et al., 2010), and PU.”
Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel, J.-C., Crozat, K., Dalod, M., & Mattiuz, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00009 · Cited by 194
“restore cDC1 development Higher differentiation in Treg of Batf3−/− CD4+ T cells (35)”
BackgroundInfluentialSaddawi-Konefka, R., O’Farrell, A., Faraji, F., Clubb, L., Allevato, M. M., Jensen, S. M., Yung, B. S., Wang, Z., Wu, V. H., Anang, N.-A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31941-w · Cited by 189
Backer, R., Schwandt, T., Greuter, M., Oosting, M., Jüngerkes, F., Tüting, T., Boon, L., O’Toole, T., Kraal, G., Limmer, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909541107 · Cited by 191
“Furthermore, they are important for the generation of antitumor specific immune responses and the elimination of tumors in vivo (17).”
BackgroundDendritic Cell-Targeted Vaccines
Cohn, L., & Delamarre, L. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00255 · Cited by 191
Role of the immunosuppressive microenvironment in immunotherapy
Tormoen, G. W., Crittenden, M. R., & Gough, M. J. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.08.018 · Cited by 189
Viral Respiratory Pathogens and Lung Injury
Clementi, N., Ghosh, S., De Santis, M., Castelli, M., Criscuolo, E., Zanoni, I., Clementi, M., & Mancini, N. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00103-20 · Cited by 189
Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity
Yang, C., Jin, J., Yang, Y., Sun, H., Wu, L., Shen, M., Hong, X., Li, W., Lu, L., Cao, D., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.012 · Cited by 189
Nixon, B. G., Kuo, F., Ji, L., Liu, M., Capistrano, K., Do, M., Franklin, R. A., Wu, X., Kansler, E. R., Srivastava, R. M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.002 · Cited by 187
Jelinek, I., Leonard, J. N., Price, G. E., Brown, K. N., Meyer-Manlapat, A., Goldsmith, P. K., Wang, Y., Venzon, D., Epstein, S. L., & Segal, D. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002845 · Cited by 190
Martínez‐López, M., Iborra, S., Conde‐Garrosa, R., & Sancho, D. (2015) · European Journal of Immunology · doi:10.1002/eji.201444651 · Cited by 188
In vivo function of Langerhans cells and dermal dendritic cells
Kaplan, D. H. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.08.006 · Cited by 189
Newman, J. H., Chesson, C. B., Herzog, N. L., Bommareddy, P. K., Aspromonte, S. M., Pepe, R., Estupinian, R., Aboelatta, M. M., Buddhadev, S., Tarabichi, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904022116 · Cited by 187
“S4) that have been shown to be important in antitumor and antipathogen (including oncolytic virus) immune responses (29, 30).”
BackgroundInfluentialCritical Roles of a Dendritic Cell Subset Expressing a Chemokine Receptor, XCR1
Yamazaki, C., Sugiyama, M., Ohta, T., Hemmi, H., Hamada, E., Sasaki, I., Fukuda, Y., Yano, T., Nobuoka, M., Hirashima, T., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202798 · Cited by 184
“CD8a+ DCs are also ablated in the mutant mice lacking a basic leucine zipper transcription factor, ATF-like 3 (BATF3) (19).”
BackgroundInfluentialNakamura, T., Kawai, M., Sato, Y., Maeki, M., Tokeshi, M., & Harashima, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01182 · Cited by 186
den Haan, J. M. M., Arens, R., & van Zelm, M. C. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.10.011 · Cited by 185
“Studies using mice deficient in CD8+ DCs demonstrated that these cells are essential for the induction of anti-viral and anti-tumor CD8 T cell response [35,36].”
BackgroundCrozat, K., Guiton, R., Guilliams, M., Henri, S., Baranek, T., Schwartz‐Cornil, I., Malissen, B., & Dalod, M. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00868.x · Cited by 186
“Batf3 ⁄ ) mice presented a drastic quantitative decrease in the induction of CD8 T cells in response to tumor injection or WNV infection and a strong reduction in the killing in vivo of target cells presenting relevant peptides, as compared with WT animals (43).”
BackgroundInfluentialDendritic cell type 3 arises from Ly6C+ monocyte-dendritic cell progenitors
Liu, Z., Wang, H., Li, Z., Dress, R. J., Zhu, Y., Zhang, S., De Feo, D., Kong, W. T., Cai, P., Shin, A., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.001 · Cited by 185
Sichien, D., Lambrecht, B. N., Guilliams, M., & Scott, C. L. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.8 · Cited by 184
Canton, J., Blees, H., Henry, C. M., Buck, M. D., Schulz, O., Rogers, N. C., Childs, E., Zelenay, S., Rhys, H., Domart, M.-C., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00824-x · Cited by 181
The tumor microenvironment’s role in the response to immune checkpoint blockade
Aliazis, K., Christofides, A., Shah, R., Yeo, Y. Y., Jiang, S., Charest, A., & Boussiotis, V. A. (2025) · Nature Cancer · doi:10.1038/s43018-025-00986-3 · Cited by 178
“In the TME, CD103 + DCs form a sparse population that depends on GM-CSF and FMS-related receptor tyrosine kinase 3 ligand (FLT3L) and expresses IRF8, ZBTB46 and BATF3 transcription factors 77,78 .”
Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
Medrano, R. F. V., Hunger, A., Mendonça, S. A., Barbuto, J. A. M., & Strauss, B. E. (2017) · Oncotarget · doi:10.18632/oncotarget.19531 · Cited by 182
“, spontaneously regresses after being inoculated in immunocompetent mice) are not able to reject them [20] and even more critically, do not respond to checkpoint blockade immunotherapy [21].”
BackgroundImmune cell subset differentiation and tissue inflammation
Fang, P., Li, X., Dai, J., Cole, L., Camacho, J. A., Zhang, Y., Ji, Y., Wang, J., Yang, X.-F., & Wang, H. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0637-x · Cited by 183
NFIL3/E4BP4 is a key transcription factor for CD8α+ dendritic cell development
Kashiwada, M., Pham, N.-L. L., Pewe, L. L., Harty, J. T., & Rothman, P. B. (2011) · Blood · doi:10.1182/blood-2010-07-295873 · Cited by 182
MacNabb, B. W., Chen, X., Tumuluru, S., Godfrey, J., Kasal, D. N., Yu, J., Jongsma, M. L. M., Spaapen, R. M., Kline, D. E., & Kline, J. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.016 · Cited by 181
Ontogeny and Functional Specialization of Dendritic Cells in Human and Mouse
Haniffa, M., Collin, M., & Ginhoux, F. (2013) · Advances in Immunology · doi:10.1016/b978-0-12-417028-5.00001-6 · Cited by 181
Takenaka, M. C., & Quintana, F. J. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-016-0587-8 · Cited by 178
“CD8α cDCs efficiently present exogenous antigens to CD8 T cells; these cells also require Id2 and the basic leucine zipper transcription factor, ATF-like 3 (Batf3) for their differentiation [25, 26], but a Batf3-independent pathway has also been described for their generation [27].”
BackgroundLow neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
Westcott, P. M. K., Sacks, N. J., Schenkel, J. M., Ely, Z. A., Smith, O., Hauck, H., Jaeger, A. M., Zhang, D., Backlund, C. M., Beytagh, M. C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00247-z · Cited by 175
Edelson, B. T., Bradstreet, T. R., Hildner, K., Carrero, J. A., Frederick, K. E., KC, W., Belizaire, R., Aoshi, T., Schreiber, R. D., Miller, M. J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.06.012 · Cited by 179
Dendritic Cells As Inducers of Peripheral Tolerance
Iberg, C. A., Jones, A., & Hawiger, D. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.07.007 · Cited by 178
“However, Batf3−/− mice show no spontaneous autoimmune inflammation, possibly in part due to the heterogeneity of DCs within the DC1 lineage and an incomplete absence of such DCs in certain genetic backgrounds of experimental mice [82, 83].”
BackgroundType 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis
Lin, J. H., Huffman, A. P., Wattenberg, M. M., Walter, D. M., Carpenter, E. L., Feldser, D. M., Beatty, G. L., Furth, E. E., & Vonderheide, R. H. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190673 · Cited by 178
“CD8+ T cell priming in tumor-bearing KPC mice was so profoundly impaired that findings were statistically indistinguishable from Batf3−/− mice that lack cDC1s (Hildner et al., 2008).”
BackgroundCross-presentation of cell-associated antigens by MHC class I in dendritic cell subsets
Gutiérrez-Martínez, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00363 · Cited by 175
“In vivo evidence obtained in Batf3−/− mice (50) and in vitro silencing studies in human CD34+ progenitors identified Batf3 as a transcription factor relevant for cDC1 development in both species (51).”
BackgroundYu, C. I., Becker, C., Wang, Y., Marches, F., Helft, J., Leboeuf, M., Anguiano, E., Pourpe, S., Goller, K., Pascual, V., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.004 · Cited by 176
“Recent studies in the mouse have established that tissueresident DCs arise from two distinct lineages, the Batf3, IRF8, Id2-dependent and Batf3, IRF8, Id2-independent lineage (Edelson et al., 2010; Ginhoux et al., 2009; Hashimoto et al., 2011; Hildner et al., 2008).”
BackgroundThe DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice
Iborra, S., Izquierdo, H. M., Martínez-López, M., Blanco-Menéndez, N., Reis e Sousa, C., & Sancho, D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60660 · Cited by 176
Different cross-presentation pathways in steady-state and inflammatory dendritic cells
Segura, E., Albiston, A. L., Wicks, I. P., Chai, S. Y., & Villadangos, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910295106 · Cited by 173
“We also investigated the role of IRAP in the in vivo induction of cytotoxic T lymphocytes (CTL), a process mainly dependent on cross-presentation by CD8 DC (2, 14).”
BackgroundCryptic activation of an Irf8 enhancer governs cDC1 fate specification
Durai, V., Bagadia, P., Granja, J. M., Satpathy, A. T., Kulkarni, D. H., Davidson, J. T., Wu, R., Patel, S. J., Iwata, A., Liu, T.-T., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0450-x · Cited by 172
Innate Control of Adaptive Immunity: Beyond the Three-Signal Paradigm
Jain, A., & Pasare, C. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1602000 · Cited by 172
Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response
Schiavoni, G., Mattei, F., & Gabriele, L. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00483 · Cited by 169
“In this view, the combined use of chemotherapy or radiotherapy that kill cancer cells, providing source of Ag for DC, with exogenous IFN-I or compounds capable of inducing IFN-I in situ may be viewed as promising strategies for boosting DC cross-presentation and CTL induction within the tumor microenvironment (Figure…”
BackgroundInfluentialWhite paper on microbial anti-cancer therapy and prevention
Forbes, N. S., Coffin, R. S., Deng, L., Evgin, L., Fiering, S., Giacalone, M., Gravekamp, C., Gulley, J. L., Gunn, H., Hoffman, R. M., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0381-3 · Cited by 168
Antigen presentation by dendritic cells in vivo
Segura, E., & Villadangos, J. A. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.011 · Cited by 168
Intestinal lamina propria dendritic cells maintain T cell homeostasis but do not affect commensalism
Welty, N. E., Staley, C., Ghilardi, N., Sadowsky, M. J., Igyártó, B. Z., & Kaplan, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130728 · Cited by 168
“BatF3/ mice (Hildner et al., 2008) were a gift from K. Murphy (Washington University, St. Louis, MO).”
MethodKawagoe, T., Takeuchi, O., Takabatake, Y., Kato, H., Isaka, Y., Tsujimura, T., & Akira, S. (2009) · Nature Immunology · doi:10.1038/ni.1771 · Cited by 168
Emerging Principles in Myelopoiesis at Homeostasis and during Infection and Inflammation
Schultze, J. L., Mass, E., & Schlitzer, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.019 · Cited by 167
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites
Perng, P., & Lim, M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00153 · Cited by 166
Novel Murine Dendritic Cell Lines: A Powerful Auxiliary Tool for Dendritic Cell Research
Fuertes Marraco, S. A., Grosjean, F., Duval, A., Rosa, M., Lavanchy, C., Ashok, D., Haller, S., Otten, L. A., Steiner, Q.-G., Descombes, P., et al. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00331 · Cited by 165
“Furthermore, distinct antigen presentation capacities have been attributed to different DC subsets, with CD8α+ DC being uniquely capable of antigen cross-presentation (Hildner et al., 2008).”
BackgroundKastenmüller, K., Wille-Reece, U., Lindsay, R. W. B., Trager, L. R., Darrah, P. A., Flynn, B. J., Becker, M. R., Udey, M. C., Clausen, B. E., Igyarto, B. Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45416 · Cited by 167
Guermonprez, P., Helft, J., Claser, C., Deroubaix, S., Karanje, H., Gazumyan, A., Darasse-Jèze, G., Telerman, S. B., Breton, G., Schreiber, H. A., et al. (2013) · Nature Medicine · doi:10.1038/nm.3197 · Cited by 167
Organization of the mouse and human DC network
Schlitzer, A., & Ginhoux, F. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.11.002 · Cited by 164
“In the case of CD8 T cell induction, the importance of cross-presentation by CD8a/CD103 DCs has been convincingly illustrated following challenge with immunogenic tumors and during infection with West Nile, murine Cytomegalovirus, Influenza virus, Herpes simplex virus (HSV) and Toxoplasma gondii [17 ,19,20 ].”
BackgroundDC subsets in positive and negative regulation of immunity
Coquerelle, C., & Moser, M. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00887.x · Cited by 165
“(75), who found that deletion of the transcription factor Batf3 ablated the development of this subset.”
BackgroundEstrogen Receptor-Dependent Regulation of Dendritic Cell Development and Function
Laffont, S., Seillet, C., & Guéry, J.-C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00108 · Cited by 165
Transcriptional Networks Driving Dendritic Cell Differentiation and Function
Nutt, S. L., & Chopin, M. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.005 · Cited by 163
Ferris, S. T., Carrero, J. A., Mohan, J. F., Calderon, B., Murphy, K. M., & Unanue, E. R. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.012 · Cited by 164
“Batf3 / allele (Hildner et al., 2008) was backcrossed to the NOD background by speed congenic approaches and confirmed by microsatellite analysis (see Table S1 available online).”
InfluentialSelf-citationMelaiu, O., Chierici, M., Lucarini, V., Jurman, G., Conti, L. A., De Vito, R., Boldrini, R., Cifaldi, L., Castellano, A., Furlanello, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19781-y · Cited by 163
Zhivaki, D., Borriello, F., Chow, O. A., Doran, B., Fleming, I., Theisen, D. J., Pallis, P., Shalek, A. K., Sokol, C. L., Zanoni, I., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108381 · Cited by 163
“This finding is in accordance with studies showing that cDC1s are required for anti-tumor T cell responses in other experimental contexts (Hildner et al., 2008; Ferris et al., 2020).”
Dendritic cell subsets in the intestinal lamina propria: Ontogeny and function
Persson, E. K., Scott, C. L., Mowat, A. M., & Agace, W. W. (2013) · European Journal of Immunology · doi:10.1002/eji.201343740 · Cited by 162
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
Lin, H., Kryczek, I., Li, S., Green, M. D., Ali, A., Hamasha, R., Wei, S., Vatan, L., Szeliga, W., Grove, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.023 · Cited by 159
“DC1s are genetically absent in Batf3−/− mice (Hildner et al., 2008) (Fig.”
BackgroundZagorulya, M., Yim, L., Morgan, D. M., Edwards, A. W., Torres-Mejia, E., Momin, N., McCreery, C. V., Zamora, I., Horton, B. L., Fox, J. G., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.010 · Cited by 180
The Immunologic Functions of the Neonatal Fc Receptor for IgG
Rath, T., Kuo, T. T., Baker, K., Qiao, S.-W., Kobayashi, K., Yoshida, M., Roopenian, D., Fiebiger, E., Lencer, W. I., & Blumberg, R. S. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9768-y · Cited by 156
“However, the antigens generated for presentation by MHC class I molecules to CD8+ T cells are derived from the processing of cytosolic proteins by proteasomes and the transport of these nominal peptides into the endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP) [77, 78].”
InfluentialCancer cells impair monocyte-mediated T cell stimulation to evade immunity
Elewaut, A., Estivill, G., Bayerl, F., Castillon, L., Novatchkova, M., Pottendorfer, E., Hoffmann-Haas, L., Schönlein, M., Nguyễn, T. C. B., Lauss, M., et al. (2024) · Nature · doi:10.1038/s41586-024-08257-4 · Cited by 192
Intestinal dendritic cells in the regulation of mucosal immunity
Bekiaris, V., Persson, E. K., & Agace, W. W. (2014) · Immunological Reviews · doi:10.1111/imr.12194 · Cited by 158
“BATF3 is highly expressed in CD8a LN resident DCs (35) and genetic ablation of BATF3 results in a loss of CD8a DCs (35) strongly suggesting the in vivo relevance of BATF3-JUN dimers as positive regulators of normal DC development.”
BackgroundYi, T., & Cyster, J. G. (2013) · eLife · doi:10.7554/elife.00757 · Cited by 156
“…in DC subsets, CD4+ and DN DCs have been most strongly implicated in priming CD4 T cell responses against exogenous antigens whereas CD8+ DCs have a more prominent role in crosspresenting antigens and promoting CD8 T cell responses (Pooley et al., 2001; Dudziak et al., 2007; Hildner et al., 2008).”
BackgroundThe role of dendritic cells in cancer
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.07.006 · Cited by 157
Kim, T. S., Gorski, S. A., Hahn, S., Murphy, K. M., & Braciale, T. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.02.004 · Cited by 156
“129S6/SvEv background were previously generated (Hildner et al., 2008).”
InfluentialBar-On, L., Birnberg, T., Lewis, K. L., Edelson, B. T., Bruder, D., Hildner, K., Buer, J., Murphy, K. M., Reizis, B., & Jung, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001562107 · Cited by 156
“Together with the results of the Flt3L exposure, this result indicates that developmental requirements of CX3CR1 + CD8α+ DC are distinct from those of classical CD8α+ DC. Collectively these findings establish that CD11chi CX3CR1 + CD8α+ cells are DC but lack hallmark features assigned to classical CD8α+ DC, such as IL…”
BackgroundMethodT Cell Fate at the Single-Cell Level
Buchholz, V. R., Schumacher, T. N. M., & Busch, D. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112014 · Cited by 156
Sosinowski, T., White, J. T., Cross, E. W., Haluszczak, C., Marrack, P., Gapin, L., & Kedl, R. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203149 · Cited by 149
Lymph node – an organ for T‐cell activation and pathogen defense
Gasteiger, G., Ataide, M. A., & Kastenmüller, W. (2016) · Immunological Reviews · doi:10.1111/imr.12399 · Cited by 177
“In addition, the notion that inflammatory signaling is required within dying cells to stimulate cross-priming (96) and that those subsets of DCs that are specialized for cross-presentation have non-redundant functions in antiviral and antitumor immunity (97, 98) support the interpretation that cross-presentation is an…”
BackgroundAkalu, Y. T., Rothlin, C. V., & Ghosh, S. (2017) · Immunological Reviews · doi:10.1111/imr.12522 · Cited by 153
Molecular Control of Steady-State Dendritic Cell Maturation and Immune Homeostasis
Hammer, G. E., & Ma, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074929 · Cited by 154
Metadata
- Authors
- Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., Schreiber, R. D., Murphy, T. L., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
- Corresponding author
- Murphy, Kenneth M.
- ORCID
- Venue
- Science
- Published
- 2008-11-14
- Volume
- 322
- Issue
- 5904
- Pages
- 1097-1100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2756611
- OpenAlex
- W2046505430
- Cited by
- 2,081
- References
- 29
- Citations by year
- 2026: 117 · 2025: 150 · 2024: 142 · 2023: 129 · 2022: 161 · 2021: 167 · 2020: 182 · 2019: 129 · 2018: 109 · 2017: 133 · 2016: 115 · 2015: 105 · 2014: 92 · 2013: 89 · 2012: 90
- FWCI
- 23.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- Batf3, CD8α+ dendritic cells, cross-presentation, West Nile virus, tumor rejection, dendritic cell development, transcription factors, antitumor immunity
- MeSH terms
- Animals, Antibodies, Viral, Cytotoxicity, Immunologic, Dendritic Cells, Female, Fibrosarcoma, Lymphocyte Activation, Male, Mice, Inbred C57BL, Repressor Proteins, Spleen, T-Lymphocytes, Cytotoxic, West Nile Fever, West Nile virus, CD4-Positive T-Lymphocytes, CD8 Antigens, Adoptive Transfer, Cross-Priming, Basic-Leucine Zipper Transcription Factors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.